Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.015
Sell
RSI(14)
48.789
Neutral
STOCH(KDJ)(9,3,3)
57.459
Buy
ATR(14)
0.180
Low Volatility
CCI(14)
-20.971
Neutral
Williams %R
60.000
Sell
TRIX(12,20)
-0.392
Sell
StochRSI(14)
61.744
Sell
Iovance Biotherapeutics Inc
IOVA2.325USD
-0.045-1.90%
Market hours （ET）Quotes delayed by 15 min
794.96MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Currency: USD Updated：2025-09-09Key Insights
The company's fundamentals are relatively weak. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
12
analysts
Buy
Current Rating
9.100
Target Price
+282.35%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.
Fairly Valued
The company’s latest is -1.95, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 271.34M shares, decreasing 9.52% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 25.03M shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.42.
Financial Health
Currency: USD Updated：2025-09-09The company's current financial score is 6.16, which is lower than the Pharmaceuticals & Medical Research industry's average of 6.80. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 49.32M, representing a year-over-year increase of 6798.46%, while its net profit experienced a year-over-year increase of 2.82%.
Score
Financials
2.85
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
7.12
Operational Efficiency
7.03
Growth Potential
6.73
Shareholder Returns
7.06
Company Valuation
Currency: USD Updated：2025-09-09The company’s current valuation score is 1.20, which is lower than the Pharmaceuticals & Medical Research industry's average of 1.64. Its current P/E ratio is -1.99, which is -20.41% below the recent high of -1.59 and -22.69% above the recent low of -2.44.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 158/686
No Data
Earnings Forecast
Currency: USD Updated：2025-09-09The company’s current earnings forecast score is 7.17, which is lower than the Pharmaceuticals & Medical Research industry's average of 7.96. The average price target for Iovance Biotherapeutics Inc is 7.50, with a high of 20.00 and a low of 1.00.
Score
Support & Resistance
No Data
Analyst Rating
Based on
12
analysts
Buy
Current Rating
9.100
Target Price
+283.97%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
555
Total
5
Median
6
Average
Company name
Ratings
Analysts
Iovance Biotherapeutics Inc
IOVA
12
CRISPR Therapeutics AG
CRSP
30
Ionis Pharmaceuticals Inc
IONS
27
Intellia Therapeutics Inc
NTLA
27
Exact Sciences Corp
EXAS
26
IQVIA Holdings Inc
IQV
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated：2025-09-09The company’s current price momentum score is 7.12, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 2.93 and the support level at 1.91, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
2.330
Sell
MA10
2.317
Buy
MA20
2.412
Sell
MA50
2.398
Sell
MA100
2.372
Sell
MA200
4.100
Sell
Institutional Confidence
Currency: USD Updated：2025-09-09The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals & Medical Research industry's average of 6.02. The latest institutional shareholding proportion is 81.00%, representing a quarter-over-quarter decrease of 3.67%. The largest institutional shareholder is The Vanguard, holding a total of 25.03M shares, representing 6.92% of shares outstanding, with 23.30% decrease in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
MHR Fund Management LLC
Quogue Capital L.L.C.
BlackRock Institutional Trust Company, N.A.
Long Focus Capital Management LLC
State Street Global Advisors (US)
Invenomic Capital Management LP
Geode Capital Management, L.L.C.
1
2
Risk Assessment
Currency: USD Updated：2025-09-09The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals & Medical Research mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 2.98, which is lower than the Pharmaceuticals & Medical Research industry's average of 3.51. The company's beta value is 0.83. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.84
VaR
+7.10%
240-Day Maximum Drawdown
+86.48%
240-Day Volatility
+111.28%
Return
Best Daily Return
60 days
+26.84%
120 days
+26.84%
5 years
+31.48%
Worst Daily Return
60 days
-20.08%
120 days
-44.79%
5 years
-53.57%
Sharpe Ratio
60 days
+0.61
120 days
+0.02
5 years
-0.18
Risk Assessment
Maximum Drawdown
240 days
+86.48%
3 years
+90.50%
5 years
+96.84%
Return-to-Drawdown Ratio
240 days
-0.89
3 years
-0.27
5 years
-0.19
Skewness
240 days
-0.82
3 years
+0.35
5 years
-0.69
Volatility
Realised Volatility
240 days
+111.28%
5 years
+91.30%
Standardised True Range
240 days
+15.42%
5 years
+37.25%
Downside Risk-Adjusted Return
120 days
+2.92%
240 days
+2.92%
Maximum Daily Upside Volatility
60 days
+120.52%
Maximum Daily Downside Volatility
60 days
+91.50%
Liquidity
Average Turnover Rate
60 days
+5.20%
120 days
+4.52%
5 years
--
Turnover Deviation
20 days
+42.35%
60 days
+64.34%
120 days
+42.93%
Peer Comparison
Currency: USD Updated：2025-09-09Iovance Biotherapeutics Inc
IOVA
5.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Royalty Pharma PLC
RPRX
7.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
7.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Stoke Therapeutics Inc
STOK
7.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
7.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Protagonist Therapeutics Inc
PTGX
7.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.
